Both PTP1B and AKR1B1 are, thus, currently emerging as suitable targets to be modulated with drug-like small molecules to discover new therapeutics for insulin resistance and obesity [12,13]. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.